BPC-157: What the Studies Really Show, and Its Status in Canada

On social media, BPC-157 is often called the peptide that “heals everything.” Athletes, influencers and even some clinics praise its effects on injuries. What is the reality? Here is an overview based on the most recent scientific reviews and Health Canada’s positions. We give no dosages, no protocols and no seller addresses.

In this article

1. What is BPC-157?
2. What the studies show
3. Why “it works in rats” is not enough
4. Why so much hype?
5. Legal status in Canada
6. What to do about an injury that will not heal
7. How to read a BPC-157 claim online
8. Frequently asked questions
9. Sources

What is BPC-157?

The name stands for Body Protection Compound-157. It is a synthetic peptide of 15 amino acids, derived from a protein found in gastric juice. Researchers have studied it since the 1990s for possible effects on healing: new blood vessel formation, fibroblast activity, reduced inflammation. These mechanisms were observed in the lab and in animals.

What the studies show

The 2025 systematic review (HSS Journal)

Researchers reviewed all the literature published up to June 2024. Of 544 articles identified, 36 studies met the criteria: 35 preclinical and only one clinical.

• In animals, BPC-157 improved functional and structural measures after muscle, tendon, ligament and bone injuries.
• The only human study was retrospective: after an injection into the knee for unspecified chronic pain, 7 of 12 patients reported relief lasting more than six months. No control group, no placebo, a very small sample.
• No clinical safety data were found.

The authors conclude that the compound “shows promise,” but the evidence is level IV and V (the weakest), and adverse effects are possible because of unregulated manufacturing, contamination or unknown clinical safety.

The 2025 narrative review (Current Reviews in Musculoskeletal Medicine)

A second review reached a similar conclusion: despite broad preclinical support, human data are limited to three small pilot studies, and BPC-157 should be considered investigational.

What Canadian experts say

In CBC News’s July 2026 investigation, Stuart Phillips, a kinesiology professor at McMaster University, put it simply: “There are basically no published human efficacy trials for BPC-157.” He mentioned one small safety study from about a decade ago and a trial that only began enrolling in February 2026. Patricia Brubaker, professor emeritus of physiology at the University of Toronto, noted that animal results, dosing and safety do not necessarily translate to humans.

Question	What we know
Effectiveness in animals	Encouraging results on injured tissue
Effectiveness in humans	Not shown: one 12-patient retrospective study, a few pilot studies
Safety in humans	No solid clinical data
Human dosing	No established protocol, according to Health Canada
Status in Canada	Not authorized as a drug or as a natural health product
Sport	Banned in professional sport

Why “it works in rats” is not enough

Most molecules that look promising in animals fail when tested in humans, either because they do not work or because they cause unexpected side effects. That is exactly why a drug goes through ever-larger clinical trials before it is authorized. BPC-157 has not passed those steps. Until it does, nobody can tell you what dose, if any, would be safe, or who should avoid it altogether.

Why so much hype?

BPC-157 ticks every box of a viral product: a technical name that sounds trustworthy, plausible biological mechanisms, dramatic testimonials and a simple promise, faster healing. The animal studies are real, which gives an appearance of seriousness. But a testimonial cannot tell you whether the injury would have healed on its own, whether the effect was a placebo, or whether the product really contained what the label said. Only controlled human trials can answer those questions, and they do not exist yet.

Legal status in Canada

Health Canada told CBC News that BPC-157 has not been authorized, that its safety, efficacy and quality have not been assessed, and that there is limited scientific evidence to support its use, including a lack of established human dosing protocols.

In 2026:

• BPC-157 was among the unauthorized seized products listed in Health Canada’s April 9 advisory;
• on May 7, Health Canada recalled BPC-157 and GHK-Cu powders sold to pharmacies as unauthorized active pharmaceutical ingredients;
• in July, CBC’s investigation revealed that some doctors prescribe it as an oral compounded product, a grey zone experts want closed.

For the full picture, read our guide are peptides legal in Canada?

What to do about an injury that will not heal

Tendinitis, knee pain or a lingering muscle injury deserves an assessment. A doctor or physiotherapist can make a diagnosis and suggest a rehabilitation program, usually built on progressive strengthening. In most provinces, you can see a physiotherapist without a referral. For keeping muscle in general, our gentle 4-week plan is a good starting point, after professional advice if you are injured.

How to read a BPC-157 claim online

Most enthusiastic BPC-157 content cites animal studies as if they applied to people. Before believing a claim, check whether the result comes from humans, whether there was a comparison group, and whether the source is a published study or a sales page. If the answer is unclear, treat the claim as unproven and discuss it with a doctor, pharmacist or physiotherapist instead.

Frequently asked questions

This article is for information only and does not replace advice from a health professional. Talk to your doctor, pharmacist or a registered dietitian before changing your treatment, diet or exercise.